Le Lézard
Classified in: Health
Subjects: PLW, IMA

Stratus® Medical announces continued expansion of its intellectual property coverage in Europe with additions to its global patent portfolio for the NIMBUS® Electrosurgical RF Multitined Expandable Electrode and registration of a Community design for new platform technology in development


MAGNOLIA, Texas, April 29, 2024 /PRNewswire/ -- Stratus® Medical, a company focused on improving clinical outcomes for chronic pain patients by advancing radiofrequency (RF) technology for the treatment of pain, announced today the expansion of patent protection in Europe for its NIMBUS® Electrosurgical RF Multitined Expandable Electrode ("NIMBUS") with the issuance of European Patent Numbers EP3556308 and EP3750501. Both patents have been validated in the United Kingdom, Ireland, and Spain and as Unitary Patents covering France, Germany, Italy, and all other countries under the Unitary Patent system. The Company's global patent portfolio for NIMBUS now includes 37 grants, of which 16 are national validations and Unitary Patents stemming from four separate European applications and five are U.S. patents, and further includes five pending applications and registrations.

Additionally, the Company has registered a Community design with the European Union Intellectual Property Office for its forthcoming platform technology, which is in late-stage development. This platform technology has not yet been submitted to or cleared by the FDA and has not yet received its CE Mark. Six U.S. and PCT applications are pending for the Company's forthcoming technologies.

Bret Boudousquie, Stratus Medical's CEO, stated, "Stratus Medical has made significant investment in product development projects to advance RF technology for the treatment of pain. We understand the importance of protecting both our valuable RF ablation technologies that are rapidly gaining market share and our future technologies that are in development. These recently issued European patents are particularly important as we continue to gain momentum with NIMBUS in Europe."

About Stratus® Medical ? Stratus Medical's mission is to improve clinical outcomes for chronic pain patients by advancing RF technology. NIMBUS, in combination with a radiofrequency (RF) generator and thermocouple probe, is intended for use in RF heat lesion procedures for relief of pain. NIMBUS, which is FDA cleared and CE marked, is easy to implement into existing workflow, has demonstrated reduced procedure time, has been validated to provide durable and sustained pain relief in independent clinical studies, and delivers substantial savings for our customers. Stratus Medical continues to invest in developing technologies that are aligned with our mission. We are headquartered in Magnolia, Texas. 

Media Contact
Cody Jorgensen
Director, Marketing
Stratus Medical
346-703-0642
[email protected]
https://stratusmedical.com

SOURCE Stratus Medical


These press releases may also interest you

at 16:11
A new partnership between the Registered Nurses' Association of Ontario (RNAO) and the Indigenous Primary Health Care Council (IPHCC) aims to build a reciprocal relationship that fosters Indigenous representation at decision-making tables within RNAO...

at 16:10
Contineum Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of...

at 16:10
Savara Inc. , a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On May 14, 2024, the Compensation Committee of Savara's Board of Directors granted the...

at 16:10
CareDx, Inc. ? The Transplant Companytm ? a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers ? today...

at 16:10
Exicure, Inc. , has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force,...

at 16:05
Axonics, Inc. today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics F15tm recharge-free sacral neuromodulation (SNM) system in Australia to treat adults with overactive...



News published on and distributed by: